CN113288991A - Traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof - Google Patents
Traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof Download PDFInfo
- Publication number
- CN113288991A CN113288991A CN202110707645.9A CN202110707645A CN113288991A CN 113288991 A CN113288991 A CN 113288991A CN 202110707645 A CN202110707645 A CN 202110707645A CN 113288991 A CN113288991 A CN 113288991A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- anxiety
- depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 33
- 230000036506 anxiety Effects 0.000 title claims abstract description 33
- 210000005075 mammary gland Anatomy 0.000 title claims abstract description 28
- 206010020718 hyperplasia Diseases 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 19
- 241000628997 Flos Species 0.000 claims abstract description 15
- 239000009526 Fructus Akebiae Substances 0.000 claims abstract description 13
- 244000141009 Hypericum perforatum Species 0.000 claims abstract description 13
- 235000017309 Hypericum perforatum Nutrition 0.000 claims abstract description 13
- 240000004307 Citrus medica Species 0.000 claims abstract description 11
- 241000220317 Rosa Species 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000012153 distilled water Substances 0.000 claims abstract description 7
- 238000007873 sieving Methods 0.000 claims abstract description 7
- 241000202726 Bupleurum Species 0.000 claims abstract description 5
- 244000164480 Curcuma aromatica Species 0.000 claims abstract description 4
- 235000003398 Curcuma aromatica Nutrition 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000001256 steam distillation Methods 0.000 claims abstract description 4
- 239000000341 volatile oil Substances 0.000 claims abstract description 4
- 241000255789 Bombyx mori Species 0.000 claims description 15
- 241000237502 Ostreidae Species 0.000 claims description 10
- 235000020636 oyster Nutrition 0.000 claims description 10
- 240000007126 Citrus medica var. sarcodactylis Species 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 4
- 238000004659 sterilization and disinfection Methods 0.000 claims description 4
- 208000020401 Depressive disease Diseases 0.000 claims description 3
- 239000004698 Polyethylene Substances 0.000 claims description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- -1 polyethylene Polymers 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 241000255791 Bombyx Species 0.000 abstract 3
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 12
- 210000000481 breast Anatomy 0.000 description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000000004 hemodynamic effect Effects 0.000 description 7
- 102000003946 Prolactin Human genes 0.000 description 6
- 108010057464 Prolactin Proteins 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229940097325 prolactin Drugs 0.000 description 6
- 206010006272 Breast mass Diseases 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 4
- 239000000186 progesterone Substances 0.000 description 4
- 229960003387 progesterone Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 206010006298 Breast pain Diseases 0.000 description 3
- 208000006662 Mastodynia Diseases 0.000 description 3
- 206010054107 Nodule Diseases 0.000 description 3
- 208000030270 breast disease Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 235000008326 Trichosanthes anguina Nutrition 0.000 description 2
- 244000078912 Trichosanthes cucumerina Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000000546 chi-square test Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 241000157282 Aesculus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000004883 areola Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000010181 horse chestnut Nutrition 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000010831 paired-sample T-test Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Insects & Arthropods (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Animal Husbandry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression, which is prepared from the following main raw materials: bupleuri radix, rhizoma Cyperi, radix Curcumae, Concha Ostreae, Bombyx Batryticatus, fructus Citri Sarcodactylis, fructus Citri, flos Rosae Rugosae, flos Pruni mume, fructus Akebiae, and herba Hyperici perforati. The invention also discloses a preparation method of the traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression, which comprises the following steps: pulverizing Bombyx Batryticatus into Bombyx Batryticatus powder, extracting with ethanol twice, filtering, and collecting the first extractive solution; extracting volatile oil of rose, flos Pruni mume and fructus Citri Sarcodactylis according to formula amount by steam distillation, and collecting to obtain second extractive solution; mixing the bupleurum, the rhizoma cyperi, the curcuma aromatica, the citron, the hypericum perforatum and the fructus akebiae according to the formula amount, adding sufficient distilled water, decocting for 30-60 minutes, and sieving by a 80-mesh sieve to obtain a third extracting solution; the traditional Chinese medicine cataplasm provided by the invention can be used for treating diseases and improving the quality of life; the cataplasma is convenient to use, and avoids the pain of oral administration of traditional Chinese medicines.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and a preparation method thereof.
Background
The hyperplasia of mammary glands, namely nodules of breast in traditional Chinese medicine, is a benign breast disease with abnormal development and degeneration of mammary glands, comprises mastopathy, cystic hyperplasia of breast and the like, is clinically manifested by breast pain, breast nodules or masses, accounts for more than 80% of breast diseases treated by breast pain agglomeration in China, and accounts for 65% of benign breast lesions. Although cyclomastopathy is a benign disease of the breast, only 1.17% of which eventually develops into breast cancer, the repeated breast pain and the presence of breast lumps place a great stress on the psychology of the patient, which is an important cause of the mood of the patient, and 11.8% of patients diagnosed with depression or anxiety, respectively, and 3.9% of patients diagnosed with depression or anxiety, respectively. The fluctuation of emotion can aggravate the clinical manifestations of patients and form a mutual influence situation. Therefore, one of the key points of treating the hyperplasia of mammary glands is to reduce the negative emotion of a patient, and the medicine intervention aiming at abnormal psychology is an indispensable part of treating the hyperplasia of mammary glands.
According to the traditional Chinese medicine, the nipple of the woman belongs to the liver, the breast belongs to the stomach, the liver channel is closely related to the breast disease of the woman, the liver is a rigid organ, likes and is resistant to depression, so that the emotional depression is easy to cause depression of the liver qi, so that the emotional depression is closely related to the occurrence and development of nodules of breast, and the theory is consistent with the psychological stress theory of modern medicine. The "orthodox surgery" section also says: "melancholy hurts liver, anxiety hurts spleen, accumulates heart and will not remember, causes the meridian stuffiness and astringent, coalesces into core", indicates that liver hurts by anxiety is an important factor for the development of nodules of breast.
Disclosure of Invention
The purpose of the invention is as follows: aiming at the problems or the defects in the prior art, the invention provides a traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and a preparation method thereof.
In order to achieve the purpose, the embodiment of the invention provides a traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression, which is characterized by being prepared from the following main raw materials in parts by weight: 5-30 parts of radix bupleuri, 5-30 parts of rhizoma cyperi, 5-30 parts of radix curcumae, 10-60 parts of oyster, 5-30 parts of stiff silkworm, 5-30 parts of fingered citron, 5-15 parts of citron, 5-30 parts of rose, 5-15 parts of flos mume, 5-30 parts of fructus akebiae, and 5-30 parts of hypericum perforatum.
Further, the health-care food is prepared from the following main raw materials in parts by weight: 7-15 parts of radix bupleuri, 10-20 parts of rhizoma cyperi, 8-18 parts of radix curcumae, 32-45 parts of oyster, 9-18 parts of stiff silkworm, 6-14 parts of fingered citron, 7-12 parts of citron, 12-20 parts of rose, 7-10 parts of flos mume, 8-18 parts of fructus akebiae and 16-25 parts of hypericum perforatum.
Preferably, the composition is prepared from the following main raw materials in parts by weight: 10 parts of radix bupleuri, 15 parts of rhizoma cyperi, 12 parts of radix curcumae, 37 parts of oyster, 13 parts of stiff silkworm, 10 parts of fingered citron, 11 parts of citron, 15 parts of rose, 8 parts of flos mume, 13 parts of fructus akebiae and 19 parts of hypericum perforatum.
The embodiment of the invention also provides a preparation method of the traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression, which is characterized by comprising the following steps:
(1) the preparation method comprises the following steps of crushing the batryticated silkworm according to the formula amount to prepare stiff silkworm powder, adding 65-90% ethanol for extraction twice, extracting for 2-3 hours each time, filtering, and collecting a first extracting solution;
(2) extracting volatile oil of rose, flos Pruni mume and fructus Citri Sarcodactylis according to formula amount by steam distillation, and collecting to obtain second extractive solution;
(3) mixing the bupleurum, the rhizoma cyperi, the curcuma aromatica, the citron, the hypericum perforatum and the fructus akebiae according to the formula amount, adding sufficient distilled water, decocting for 30-60 minutes, and sieving by a 80-mesh sieve to obtain a third extracting solution;
(4) crushing oyster shells according to the formula amount, adding sufficient distilled water, decocting for 60 minutes, and sieving with a 80-mesh sieve to obtain a fourth extracting solution;
(5) adding the first extracting solution obtained in the step (1), the second extracting solution obtained in the step (2) and the third extracting solution obtained in the step (3) into the fourth extracting solution obtained in the step (4), and drying under reduced pressure by adopting a cabinet type reduced-pressure dryer to obtain dry powder;
(6) further crushing the medicinal powder obtained in the step (4) into fine powder with the granularity of more than 100 meshes by using a traditional Chinese medicine ultrafine pulverizer;
(7) at an ozone concentration of 50g/m3Air flow speed of 40m/s and air source oxygen purity>85 percent, sterilizing the fine powder obtained in the step (5) by ozone at the sterilization temperature of less than 40 ℃, preserving the medicinal components under the maximum condition, and preparing the Chinese medicinal preparation;
(8) preparing a matrix: weighing a proper amount of medical thermosol, heating to 40-60 ℃ for dissolving, and stirring for 20-40 min;
(9) and (3) taking 80-150 g of the traditional Chinese medicine preparation prepared in the step (7) and 8-15 ml of the substrate prepared in the step (8), dissolving at 40-60 ℃, uniformly stirring to form a dry thick paste, taking 0.5g of the thick paste, coating the thick paste on non-woven fabric with the thickness of 1mm, cooling, covering with a polyethylene film, and packaging to obtain the traditional Chinese medicine preparation.
Further, the fine powder prepared in the step (5) requires: 100 percent of the mixture is sieved by a 100-mesh sieve, and 95 percent of the mixture is sieved by a 120-mesh sieve.
The technical scheme of the invention has the following beneficial effects:
(1) the Chinese medicinal cataplasm for treating hyperplasia of mammary glands with anxiety and depression, which is disclosed by the invention, contains the bupleurum, the rhizoma cyperi and the radix curcumae, and has the effects of soothing liver and relieving depression, regulating qi and activating blood; the contained fingered citron, buckeye and fructus akebiae have the effects of soothing liver-qi stagnation, regulating qi and relieving pain; the contained hypericum perforatum has the effects of soothing liver-qi stagnation, reducing swelling and relieving pain, and the effective components of the hypericum perforatum have certain depression resistance; the contained snakegourd fruit and stiff silkworm have the functions of reducing phlegm, softening hardness and dissipating stagnation, are key medicines for treating hyperplasia of mammary glands, and the effective components of the snakegourd fruit and stiff silkworm have certain sedative and analgesic effects; flos Rosae Rugosae and flos Pruni mume have effects of dispersing stagnated liver qi for relieving qi stagnation, promoting blood circulation and relieving pain; the whole formula has the effects of soothing liver-qi stagnation, reducing phlegm and resolving masses, and activating blood and relieving pain.
(2) The traditional Chinese medicine cataplasm aims at special crowds of physical diseases and psychological diseases, namely 'double heart diseases', and can treat diseases and improve the life quality; meanwhile, the cataplasm is convenient to use, and avoids the pain of oral administration of traditional Chinese medicines.
(3) In the preparation method process of the traditional Chinese medicine cataplasm, the materials are divided into a plurality of groups, and different extraction modes (ethanol extraction, steam distillation and decoction) are adopted to extract the effective components respectively, so that the effective components of the extracted medicine can be effectively protected, the cataplasm is more convenient to use, has the effect of treating hyperplasia of mammary glands and anxiety and depression, and has better clinical curative effect.
Detailed Description
In order to make the technical problems, technical solutions and advantages to be solved by the present invention clearer, the following detailed description is given with reference to specific embodiments.
The invention provides a traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression, which is prepared from the following main raw materials in parts by weight: 10 parts of radix bupleuri, 15 parts of rhizoma cyperi, 12 parts of radix curcumae, 37 parts of oyster, 13 parts of stiff silkworm, 10 parts of fingered citron, 11 parts of citron, 15 parts of rose, 8 parts of flos mume, 13 parts of fructus akebiae and 19 parts of hypericum perforatum.
According to the formula, the traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands complicated with anxiety and depression is prepared by taking the traditional Chinese medicine raw materials according to the formula amount according to the following preparation method, and the preparation steps are as follows:
(1) the preparation method comprises the steps of crushing the batryticated silkworm according to the formula amount, preparing stiff silkworm powder, adding 65-90% ethanol for extraction twice, extracting for 2-3 hours each time, filtering, and collecting a first extracting solution.
(2) Extracting volatile oil of rose, flos Pruni mume and fructus Citri Sarcodactylis with water vapor distillation method, and collecting to obtain second extractive solution.
(3) Mixing the bupleurum, the rhizoma cyperi, the curcuma aromatica, the citron, the hypericum perforatum and the fructus akebiae according to the formula amount, adding sufficient distilled water, decocting for 30-60 minutes, and sieving by a 80-mesh sieve to obtain a third extracting solution.
(4) Crushing oyster shells according to the formula amount, adding sufficient distilled water, decocting for 60 minutes, and sieving with a 80-mesh sieve to obtain a fourth extracting solution.
(5) Adding the first extracting solution obtained in the step (1), the second extracting solution obtained in the step (2) and the third extracting solution obtained in the step (3) into the fourth extracting solution obtained in the step (4), and drying under reduced pressure by adopting a cabinet type reduced-pressure dryer to obtain dry powder; the fine powder prepared in the step (5) requires: 100 percent of the mixture is sieved by a 100-mesh sieve, and 95 percent of the mixture is sieved by a 120-mesh sieve.
(6) And (5) further crushing the medicinal powder obtained in the step (4) into fine powder with the granularity of more than 100 meshes by using a traditional Chinese medicine ultrafine pulverizer.
(7) At an ozone concentration of 50g/m3Air flow speed of 40m/s and air source oxygen purity>And (3) performing ozone sterilization on the fine powder obtained in the step (5) at the sterilization temperature of less than 40 ℃ at 85 percent, preserving the medicinal components under the maximum condition, and preparing the Chinese medicinal preparation.
(8) Preparing a matrix: weighing a proper amount of the medical thermosol, heating to 40-60 ℃ for dissolving, and stirring for 20-40 min.
(9) And (3) taking 80-150 g of the traditional Chinese medicine preparation prepared in the step (7) and 8-15 ml of the substrate prepared in the step (8), dissolving at 40-60 ℃, uniformly stirring to form a dry thick paste, taking 0.5g of the thick paste, coating the thick paste on non-woven fabric with the thickness of 1mm, cooling, covering with a polyethylene film, and packaging to obtain the traditional Chinese medicine preparation.
Rat experiments prove that the cataplasm prepared by the formula and the method has no toxic or side effect.
The following experimental data are combined to prove that the cataplasm prepared by the invention can be used for treating hyperplasia of mammary glands with anxiety and depression.
180 patients with standard breast surgery outpatients in traditional Chinese medicine hospital of Nantong city of 1 month to 7 months in 2019 are selected and divided into a treatment group and a control group according to a random digital table method, wherein 90 patients are selected. The patients in the two groups have no significant difference in age, onset time and onset part, and have comparability (P >0.05), which is shown in Table 1. The study was approved by the ethical committee of the institute of traditional Chinese medicine in south China.
The treatment method comprises the following steps: control group: the granule (approved by the department of pharmacy of traditional Chinese medicine, Nantong city, SU YAO character Z040001364) is administered with 200ml warm boiled water 1 dose per day in the morning and evening, 2 weeks is 1 course of treatment, and 3 courses of treatment are given in total.
Treatment groups: the cataplasm of the invention is externally applied for 3 courses on the basis of a control group.
Observation indexes are as follows: 1. anxiety, depression score: in a resting state, the emotional state of a tester is evaluated by using an anxiety self-rating scale (SAS) and a depression self-rating scale (SDS) compiled by Zung, the higher the score is, the more serious the anxiety and the depression is, the total score is 80 by adopting a four-grade scoring method, the score is converted into a percentile standard score, and the sum of the standard scores of the two scales is calculated. All points were scored as questionnaires at the time of group entry and 6 weeks after treatment.
2. Laboratory index
(1) Hormone level detection: estradiol (E2), progesterone (P) and Prolactin (PRL) levels were collected once each at the time of enrollment and 3 months after treatment, the reagents were provided by Roche; (2) color Doppler ultrasound examination: the maximum blood flow velocity (Vmax), the minimum blood flow velocity (Vmin) and the blood flow Resistance Index (RI) of the breast hemodynamic index level are detected by using a color Doppler ultrasonic diagnostic apparatus (Siemens S2000, probe frequency of 18 mHz). Collected once after 6 weeks of group entry and treatment.
Statistical method
Statistical analysis of the data was performed using SPSS 20.0. For data conforming to normal distribution, metering data is expressed in (x +/-s), independent sample t test is adopted among groups, paired sample t test is adopted in groups, and counting data is subjected to 2 test; non-parametric tests are used for data that do not conform to normal distributions. P <0.05 indicates that the difference is statistically significant.
As a result: example 1
In the study process of the invention, the data collected from the control group and the treatment group were compared, 90 persons were selected for each group, and the time of onset and the single and double-sided incidence rates were counted, with the statistical results shown in table 1.
TABLE 1 comparison of two general data sets
Note: and the chi-square test is used as the test result, T is the statistic of the T test, chi-2 is the statistic of the chi-square test, P is the judgment on the result, and P <0.05 represents that the difference has statistical significance.
The results show that: the differences in age, time of onset and distribution of unilateral or bilateral onset were not statistically significant (P >0.05) in the treated groups compared to the control group.
(1) Clinical symptom score and anxiety and depression score comparison of treatment group and control group
The difference between the clinical symptom score and the anxiety and depression score before treatment of the treatment group and the control group has no statistical significance and has comparability (P is more than 0.05); the clinical symptom score and the anxiety and depression score are reduced by comparing before and after treatment in the two groups, and the difference has statistical significance (P is less than 0.05); the clinical symptom score and the anxiety and depression score after treatment in the treatment group are lower than those in the control group, and the difference has statistical significance (P <0.05), which is shown in table 2.
TABLE 2 comparison of two groups of clinical symptom scores and anxiety-depression scores
As can be seen from table 2, the symptom score and anxiety-depression score were decreased before and after treatment in the treatment group and the control group, P <0.001, and the difference was statistically significant.
The results show that: the symptom score and the anxiety and depression score are reduced compared before and after treatment in the treatment group and the control group, which indicates that the cataplasm provided by the invention can be applied externally for 3 courses and has a certain effect on treating hyperplasia of mammary glands and anxiety and depression. The symptom scores and the anxiety and depression scores of the treated group and the control group after treatment are compared, and the effect of the cataplasm external application combined with the breast nodule eliminating granule for oral administration for 3 courses of treatment on the hyperplasia of mammary glands and the anxiety and depression is better than the effect of the breast nodule eliminating granule for internal administration of the control group.
(2) The total effective rate of the treatment group and the control group is compared
The curative group and the control group are compared with the curative, obvious effect, effective and total effective rate.
TABLE 3 comparison of the two groups of total effective rates
As can be seen from Table 3, the total effective rate of the treatment group was higher than that of the control group, and the difference was statistically significant (P < 0.05).
(3) Laboratory index comparison of treatment and control groups
Compared with the pretreatment hormone level (E2, P (progesterone), PRL) and the ultrasonic hemodynamics index (Vmax, Vmin and RI) of the control group, the difference has no statistical significance and has comparability (P > 0.05); the results of comparing the intra-and post-treatment data for the treated and control groups are shown in tables 4 and 5:
TABLE 4 comparison of hormone levels in the treated and control groups
Note: in the treatment group and the control group, the levels of E2 and PRL are reduced and the level of P (progesterone) is increased in the pre-treatment control and the post-treatment control, and the difference has statistical significance (P is less than 0.001).
TABLE 5 comparison of the ultrasonic hemodynamic indices of the treated and control groups
Note: compared with the treatment group and the control group before and after treatment, the ultrasonic hemodynamics indexes Vmax and Vmin are increased, the RI is decreased, and the difference has statistical significance.
As can be seen from tables 4 and 5, the hormone levels and the ultrasound hemodynamic indices before and after treatment in the treatment group and the control group were improved, and the differences had statistical significance (P < 0.05); compared with serum indexes and ultrasonic indexes after treatment in two groups, E2, PRL and RI in the treatment group are lower than those in the control group, P (progesterone), Vmax and Vmin are higher than those in the control group, and the difference has statistical significance (P is less than 0.05). Therefore, after the cataplasm is used for treatment, the hormone level and the hemodynamics of a patient under ultrasound can be obviously improved, female progestogen and prolactin are definitely related to the pathogenesis of hyperplasia of mammary glands, the female progestogen is related to the generation of anxiety and depression, and the hemodynamics of the mammary glands under ultrasound reflects the lightness and heaviness of the hyperplasia of the mammary glands.
When the cataplasm of the present invention is used, it should be noted that: the use is forbidden for skin allergy patients; secondly, sensitive parts such as nipple areola and the like are avoided when the patch is applied.
While the foregoing is directed to the preferred embodiment of the present invention, it will be understood by those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the invention as defined in the appended claims.
Claims (5)
1. A traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression is characterized by being prepared from the following main raw materials in parts by weight: 5-30 parts of radix bupleuri, 5-30 parts of rhizoma cyperi, 5-30 parts of radix curcumae, 10-60 parts of oyster, 5-30 parts of stiff silkworm, 5-30 parts of fingered citron, 5-15 parts of citron, 5-30 parts of rose, 5-15 parts of flos mume, 5-30 parts of fructus akebiae, and 5-30 parts of hypericum perforatum.
2. The traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression according to claim 1 is characterized by being prepared from the following main raw materials in parts by weight: 7-15 parts of radix bupleuri, 10-20 parts of rhizoma cyperi, 8-18 parts of radix curcumae, 32-45 parts of oyster, 9-18 parts of stiff silkworm, 6-14 parts of fingered citron, 7-12 parts of citron, 12-20 parts of rose, 7-10 parts of flos mume, 8-18 parts of fructus akebiae and 16-25 parts of hypericum perforatum.
3. The traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression according to claim 1 is characterized by being prepared from the following main raw materials in parts by weight: 10 parts of radix bupleuri, 15 parts of rhizoma cyperi, 12 parts of radix curcumae, 37 parts of oyster, 13 parts of stiff silkworm, 10 parts of fingered citron, 11 parts of citron, 15 parts of rose, 8 parts of flos mume, 13 parts of fructus akebiae and 19 parts of hypericum perforatum.
4. A preparation method of the traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands and anxiety depression according to any one of claims 1 to 3, which is characterized by comprising the following steps:
(1) the preparation method comprises the following steps of crushing the batryticated silkworm according to the formula amount to prepare stiff silkworm powder, adding 65-90% ethanol for extraction twice, extracting for 2-3 hours each time, filtering, and collecting a first extracting solution;
(2) extracting volatile oil of rose, flos Pruni mume and fructus Citri Sarcodactylis according to formula amount by steam distillation, and collecting to obtain second extractive solution;
(3) mixing the bupleurum, the rhizoma cyperi, the curcuma aromatica, the citron, the hypericum perforatum and the fructus akebiae according to the formula amount, adding sufficient distilled water, decocting for 30-60 minutes, and sieving by a 80-mesh sieve to obtain a third extracting solution;
(4) crushing oyster shells according to the formula amount, adding sufficient distilled water, decocting for 60 minutes, and sieving with a 80-mesh sieve to obtain a fourth extracting solution;
(5) adding the first extracting solution obtained in the step (1), the second extracting solution obtained in the step (2) and the third extracting solution obtained in the step (3) into the fourth extracting solution obtained in the step (4), and drying under reduced pressure by adopting a cabinet type reduced-pressure dryer to obtain dry powder;
(6) further crushing the medicinal powder obtained in the step (4) into fine powder with the granularity of more than 100 meshes by using a traditional Chinese medicine ultrafine pulverizer;
(7) at an ozone concentration of 50g/m3Air flow speed of 40m/s and air source oxygen purity>85 percent, sterilizing the fine powder obtained in the step (5) by ozone at the sterilization temperature of less than 40 ℃, preserving the medicinal components under the maximum condition, and preparing the Chinese medicinal preparation;
(8) preparing a matrix: weighing a proper amount of medical thermosol, heating to 40-60 ℃ for dissolving, and stirring for 20-40 min;
(9) and (3) taking 80-150 g of the traditional Chinese medicine preparation prepared in the step (7) and 8-15 ml of the substrate prepared in the step (8), dissolving at 40-60 ℃, uniformly stirring to form a dry thick paste, taking 0.5g of the thick paste, coating the thick paste on non-woven fabric with the thickness of 1mm, cooling, covering with a polyethylene film, and packaging to obtain the traditional Chinese medicine preparation.
5. The preparation method of the traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression according to claim 4, wherein the fine powder prepared in the step (5) requires: 100 percent of the mixture is sieved by a 100-mesh sieve, and 95 percent of the mixture is sieved by a 120-mesh sieve.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110707645.9A CN113288991A (en) | 2021-06-24 | 2021-06-24 | Traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof |
| CN202210675440.1A CN114939150A (en) | 2021-06-24 | 2022-06-15 | Traditional Chinese medicine emulsifiable paste for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110707645.9A CN113288991A (en) | 2021-06-24 | 2021-06-24 | Traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113288991A true CN113288991A (en) | 2021-08-24 |
Family
ID=77329531
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110707645.9A Withdrawn CN113288991A (en) | 2021-06-24 | 2021-06-24 | Traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof |
| CN202210675440.1A Withdrawn CN114939150A (en) | 2021-06-24 | 2022-06-15 | Traditional Chinese medicine emulsifiable paste for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210675440.1A Withdrawn CN114939150A (en) | 2021-06-24 | 2022-06-15 | Traditional Chinese medicine emulsifiable paste for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN113288991A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116688032A (en) * | 2023-07-24 | 2023-09-05 | 南通市中医院 | Traditional Chinese medicine sachet for treating postoperative anxiety depression of breast cancer and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104667171A (en) * | 2015-01-28 | 2015-06-03 | 慕森 | Traditional Chinese medicine for treating hyperplasia of mammary glands and preparation method of traditional Chinese medicine |
| CN104873602A (en) * | 2015-05-28 | 2015-09-02 | 河南中医学院 | Traditional Chinese medicine for treating mammary gland hyperplasia |
-
2021
- 2021-06-24 CN CN202110707645.9A patent/CN113288991A/en not_active Withdrawn
-
2022
- 2022-06-15 CN CN202210675440.1A patent/CN114939150A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104667171A (en) * | 2015-01-28 | 2015-06-03 | 慕森 | Traditional Chinese medicine for treating hyperplasia of mammary glands and preparation method of traditional Chinese medicine |
| CN104873602A (en) * | 2015-05-28 | 2015-09-02 | 河南中医学院 | Traditional Chinese medicine for treating mammary gland hyperplasia |
Non-Patent Citations (2)
| Title |
|---|
| 乔楠等: "内消乳核冲剂治疗肝郁气滞型乳腺增生症患者的", 《中华中医药杂志》 * |
| 邵继棠: "郁证之治 须分内外", 《湖北中医杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116688032A (en) * | 2023-07-24 | 2023-09-05 | 南通市中医院 | Traditional Chinese medicine sachet for treating postoperative anxiety depression of breast cancer and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114939150A (en) | 2022-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101444611B (en) | Traditional Chinese medicine composition for treating lumbocrural pain and lumbar intervertebral disc protrusion and preparation method thereof | |
| CN113288991A (en) | Traditional Chinese medicine cataplasm for treating hyperplasia of mammary glands with anxiety and depression and preparation method thereof | |
| CN110327437B (en) | Traditional Chinese medicine for treating chronic diarrhea and preparation method thereof | |
| CN104147518A (en) | Traditional Chinese medicinal capsule for treating depression and preparation method thereof | |
| CN1951447A (en) | Chinese medicinal composition for treating disease of mammary glands and preparation method thereof | |
| CN112402554B (en) | Traditional Chinese medicine composition for treating leukoencephalopathy and application thereof | |
| CN104958727B (en) | A kind of Chinese medicine composition for treating the childhood asthma paracmasis and its application | |
| CN101152532B (en) | Traditional Chinese medicine preparations for treating gynecology disease | |
| CN105362629A (en) | Female climacteric syndrome treatment pharmaceutical composition containing cortex eucommiae and preparation method of female climacteric syndrome treatment pharmaceutical composition containing cortex eucommiae | |
| CN104906394A (en) | Traditional Chinese medicine for treating liver and kidney yin deficiency and qi and blood deficiency type hypertension | |
| CN116211974B (en) | Traditional Chinese medicine composition for improving microcirculation of human body | |
| CN103479868B (en) | Traditional Chinese medicine for treating apprehensive and cowardly arrhythmia and preparation method | |
| CN111643606B (en) | Gel plaster for treating insomnia and preparation method thereof | |
| CN116509824B (en) | Traditional Chinese medicine gel and preparation process thereof | |
| CN110151870B (en) | A kind of soothing liver and strengthening spleen tune rouge Chinese materia medica preparation and preparation method thereof | |
| CN118001323B (en) | Traditional Chinese medicine composition for preventing and treating anxiety disorder and preparation method and application thereof | |
| CN116350695B (en) | New use of pharmaceutical composition for treating pulmonary nodules | |
| CN107617081A (en) | The Chinese medicine composition and its preparation and preparation method of a kind of hair growth | |
| CN106727752A (en) | Treat pharmaceutical composition of synovitis and preparation method thereof | |
| CN106619866A (en) | Traditional Chinese medicinal health soup having effect of loosening bowel to relieve constipation | |
| CN107753628A (en) | A kind of Chinese medicine composition and preparation method for treating insomnia | |
| CN101406625A (en) | Chinese medicinal composition for treating cancer as well as preparation method and use thereof | |
| CN110327429A (en) | A kind of Chinese medicine composition and the preparation method and application thereof | |
| CN105233134B (en) | A kind of Chinese medicine composition and preparation method thereof for treating menopausal syndrome | |
| CN117298213A (en) | Traditional Chinese medicine composition for treating liver depression and qi stagnation type hyperplasia of mammary glands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210824 |